2015 ISAKOS Biennial Congress ePoster #420
Quantitation of Progenitor Cells After Bone Marrow Aspirate Concentration
Jason L. Dragoo, MD, Englewood, CO UNITED STATES
Malcolm DeBaun, MD, Palo Alto, CA UNITED STATES
Richard Schaefer, PhD, Tübingen GERMANY
Stanford University, Palo Alto, USA
FDA Status Not Applicable
Summary: Both systems concentrated progenitor cell populations more than untreated bone marrow aspirate, however the systems concentrated different cell populations.
The use of bone marrow aspirate concentrate (BMAC) has become an increasingly popular method of augmenting autologous bone grafting, and treating both bony non-unions, and chondral defects. BMAC is obtained through density gradient centrifugation of bone marrow typically aspirated from the iliac crest. The principle reason for the use of BMAC as a biologic adjunct is the ability to introduce a concentrate of heterogeneous mesenchymal stem cells to the site of injury. The purpose of this study is to compare the differences in progenitor cell population of single-donor bone marrow aspirate concentrate prepared by two commercially available systems simultaneously.
After Institutional Review Board approval, bone marrow aspirate (BMA) was obtained from human donors, n=3, who where screened for significant medical history. BMA was then concentrated using the FDA approved Emcyte GenesisCS and Harvest SmartPReP 2 BMAC systems as per manufacturer’s instructions. The progenitor cell population (CD73+, CD90+, CD44+, CD271+, GD2+, CD45-) concentrated by each system was characterized using fluorescence activated cell sorting, with unprocessed BMA serving as a negative control.
Overall cell viability was unaffected by processing with both Emcyte [97.5% viable] and Harvest systems [95.0 %]. Harvest SmartPreP [7498 events/0.7% of all cells] concentrated more GD2+, CD45-cells when compared to Emcyte GenesisCS [62 events/0.0% of all cells] and control BMA [369 events/0.0% of cells]. Emcyte GenesisCS [585 events/ 0.1% of all cells] concentrated more CD271+, CD45- cells when compared to Harvest SmartPreP [29 events/ 0.0% of all cells] although both systems yielded less than control BMA [956 events/ 0.1 % of all cells]. Emcyte GenesisCS [1668 events/ 0.2% of all cells] concentrated more CD73+, CD90+, CD45- cells when compared to Harvest system [793 events/ 0.1% of all cells] and control BMA [236 events/ 0.0% of all cells]. Emcyte Genesis CS [1250 events/ 0.1% of all cells] also concentrated more CD44+, CD271+, CD45-cells than Harvest [16 events/ 0.0% of all cells] and BMA control [947 events/ 0.1% of all cells].
Our results suggest that different commercially available bone marrow concentration systems yield heterogeneous populations of progenitor cells. Both systems concentrated progenitor cell populations more than untreated bone marrow aspirate, however the systems concentrated different cell populations. The commercial market for BMAC is budding, and it is imperative to classify and compare the BMAC produced by commercially available systems to better understand the clinical potential of these products.